COVID-19 and Anti-CD14 Treatment Trial

Exclusion Criteria

• •An individual fulfilling any of the following criteria should be excluded from enrollment in the study:
• •Receiving non-invasive positive-pressure ventilation through nasal mask, face mask, or nasal plugs
• •Receiving invasive mechanical ventilation
• •Patient, surrogate, or physician not committed to full support
• •--Exception: a participant will not be excluded if he/she would receive all supportive care other than attempts at resuscitation from cardiac arrest)
• •Anticipated survival \<48 hours
• •Underlying malignancy, or other condition, with estimated life expectancy of less than two months
• •Significant pre-existing organ dysfunction prior to randomization
• •* Lung: Currently receiving home oxygen therapy as documented in medical record
• •* Heart: Pre-existing congestive heart failure defined as an ejection fraction \<20% as documented in the medical record
• •* Renal: End-stage renal disease requiring renal replacement therapy or eGFR \<30 mL/min
• •* Liver: Severe chronic liver disease defined as Child-Pugh Class C or AST or ALT \>5x upper limit of normal
• •* Hematologic: Baseline platelet count \<50,000/mm\^3
• •Presence of co-existing infection, including, but not limited to:
• •* HIV infection not virally suppressed and with pre-hospitalization CD4 counts ≤ 500 cell/mm\^3
• •* Active tuberculosis or a history of inadequately treated tuberculosis
• •* Active hepatitis B or hepatitis C viral infection
• •Ongoing immunosuppression
• •* Solid organ transplant recipient
• •* High-dose corticosteroids (equivalent to \>20 mg/prednisone/day) within the past 28 days, except for dexamethasone except for dexamethasone or equivalent treatment for COVID-19 illness
• •* Oncolytic drug therapy within the past 14 days
• •Current treatment, or treatment within 30 days or five half-lives (whichever is longer) with etanercept (Enbrel®), infliximab (Remicade®), adalimumab (Humira®), certolizumab (Cimzia®), golimumab (Simponi®), anakinra (Kineret®), rilonacept (Arcalyst®), tocilizumab (Actemra®), sarilumab (Kevzara®), siltuximab (Sylvant®), or other potent immunosuppressant or immunomodulatory drugs or treatments
• •Current treatment with an anti-viral medication for COVID-19 (e.g. hydroxychloroquine, lopinavir/ritonavir), other than remdesivir
• •Current enrollment in an interventional trial for COVID-19
• •History of hypersensitivity or idiosyncratic reaction to IC14
• •Women who are currently breastfeeding
• •Received a live-attenuated vaccine within 30 days prior to enrollment
• •Received five or more doses of remdesivir, including the loading dose, outside of the study as treatment for COVID-19, or
• •Any condition that in the opinion of the treating physician will increase the risk for the participant.